Akcea Reports Financial Results and Highlights for First Quarter 2019
May 08, 2019 16:05 ET
|
Akcea Therapeutics, Inc.
Achieved First Quarter 2019 TEGSEDI® (inotersen) Global Net Product Revenues of $7 Million Novartis exercised its option to license AKCEA-APO(a)-LRx Received marketing authorization for WAYLIVRA®...
New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN)
May 07, 2019 16:05 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
NEURO-TTR phase 3 open-label extension study showed TEGSEDI® (inotersen) treatment continued to slow progression over two-year period in patients with Hereditary ATTR amyloidosis with polyneuropathy ...
Akcea and Ionis Announce Approval of WAYLIVRA® (volanesorsen) in the European Union
May 07, 2019 08:41 ET
|
Akcea Therapeutics, Inc.
BOSTON and CARLSBAD, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS),...
Akcea Announces Upcoming Data Presentations at the 2019 American Academy of Neurology Meeting (AAN.19)
May 02, 2019 07:05 ET
|
Akcea Therapeutics, Inc.
Multiple clinical presentations at AAN focus on the long-term clinical benefits of treatment with TEGSEDI™ (inotersen) An oral presentation of long-term efficacy and safety with 2-year data from...
Akcea Therapeutics to Hold First Quarter 2019 Financial Results Webcast
April 24, 2019 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, April 24, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Wednesday, May 8th...
Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19)
March 15, 2019 16:05 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
BOSTON and CARLSBAD, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)...
Akcea и Ionis получили одобрение EU CHMP по использованию WAYLIVRATM (volanesorsen)
March 06, 2019 00:30 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
Бостон и Карлсбад, March 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (биржевый символ NASDAQ:AKCA), подразделение Ionis Pharmaceuticals, Inc., и Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
Akcea und Ionis erhalten positive Stellungnahme des CHMP zu WAYLIVRATM (Volanesorsen)
March 06, 2019 00:30 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
BOSTON, Massachusetts und CARLSBAD, Kalifornien, March 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), ein Tochterunternehmen von Ionis Pharmaceuticals, Inc. und Ionis...
Akcea et Ionis obtiennent un avis positif du CHMP de l'UE concernant WAYLIVRA™ (volanesorsen)
March 06, 2019 00:30 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
BOSTON, Massachusetts et CARLSBAD, Californie, 06 mars 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ : AKCA), filiale d’Ionis Pharmaceuticals, Inc., et Ionis Pharmaceuticals,...
Akcea en Ionis krijgen positief advies van het EU CHMP voor WAYLIVRATM (volanesorsen)
March 06, 2019 00:30 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
BOSTON, Mass. en CARLSBAD, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), een gelieerde onderneming van Ionis Pharmaceuticals, Inc., en Ionis Pharmaceuticals,...